首页 | 本学科首页   官方微博 | 高级检索  
     

益生菌对肝硬化血氨影响的实验及临床研究
引用本文:卜淑蕊,戴鹏,赵严,刘近春,闫柱. 益生菌对肝硬化血氨影响的实验及临床研究[J]. 中国微生态学杂志, 2007, 19(1): 25-26
作者姓名:卜淑蕊  戴鹏  赵严  刘近春  闫柱
作者单位:1. 山西医科大学第一医院,消化科,山西,太原,030001
2. 山西省肿瘤医院,消化科,山西,太原,030000
摘    要:目的采用动物实验及临床观察,探讨益生菌制剂培菲康治疗肝硬化高氨血症的作用机制。方法采用大鼠肝硬化模型,其中治疗组予以培菲康悬液每天灌胃治疗共8周,检测治疗组及对照组血浆内毒素指标;并选用70例肝硬化Child-Pugh分级为B级的患者,其中治疗组口服培菲康胶囊(每次2粒,每日3次)3周,观察治疗前后血浆内毒素变化。结果培菲康治疗组的肝硬化大鼠及患者血浆内毒素均明显低于对照组(P<0.05)。结论培菲康能明显降低肝硬化患者的血氨水平,可作为肝硬化患者的辅助用药。

关 键 词:培菲康  肝硬化  患者  大鼠  血氨
文章编号:1005-376X(2007)01-0025-02
收稿时间:2006-05-26
修稿时间:2006-05-26

Experimental and clinical study of BIFICO on plasma ammonia in rats and patients with liver cirrhosis
BU Shu-rui,DAI Peng,ZHAO Yan,LIU Jing-chun,YAN Zhu. Experimental and clinical study of BIFICO on plasma ammonia in rats and patients with liver cirrhosis[J]. Chinese Journal of Microecology, 2007, 19(1): 25-26
Authors:BU Shu-rui  DAI Peng  ZHAO Yan  LIU Jing-chun  YAN Zhu
Affiliation:1. Department of Gastroenterology, the 1^st Hospital of Shanxi Medical University, Taiyuan 030001, China;2, Department of Gastroenterology, the Shanxi Provincial Tumor Hospital, Taiyuan 030000, China
Abstract:Objective To investigate the effect of Bifico capsule on the levels of plasma ammonia in rats and patients with liver cirrhosis.Methods 44 Wistar rats were induced into live cirrhosis models by injecting CCL4 every 3 days for 8 weeks.70 patients with cirrhosis of Child-Pugh B stage were observed,35 patients were treated by Bifico capsule(2 capsules,triple daily) orally for three weeks.Plasma ammonia was detected before and after the therapy.Result The levels of plasma ammonia in the treatment group wes significantly lower than those in control group(P<0.05).Conclusion Bifico can reduce the level of plasma ammonia in patients with liver cirrhosis,it can be used for routine auxiliary therapy on the liver cirrhosis.
Keywords:Bifico  Liver cirrhosis  Patients  Rat  Plasma ammonia
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号